Searchable abstracts of presentations at key conferences in endocrinology

ea0060p08 | (1) | UKINETS2018

Periodic endoscopic surveillance in patients with low risk type I gastric neuroendocrine tumours (gNETs) also detects associated gastric adenocarcinoma in a subset of patients

Hu Haiyi , Exarchou Klaire , Moore Andrew , Pritchard D Mark

Background: People who have autoimmune atrophic gastritis commonly develop type 1 gNETs, but are also at increased risk of developing gastric adenocarcinoma. Type I gNET patients usually have multiple gastric polyps and have an excellent prognosis when the polyps measure.Method: Retrospective audit of type I gNET patients managed within Liverpool ENETS Centre of Excellence 2004–2018.Results: 86 patients (median age 67 years, 5...

ea0046oc1 | (1) | UKINETS2016

Netazepide, a gastrin/CCK2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis

Boyce Malcolm , Moore Andrew , Parsons Bryony , Lloyd Katie , Sagatun Liv , Thomsen Liv , Varro Andrea , Fossmark Reidar , Waldum Helge , Pritchard David M

Introduction: In a two-centre, 12-week, open trial in 16 patients with autoimmune chronic atrophic gastritis, hypergastrinaemia, multiple type 1 gastric neuroendocrine tumours (NETs), and raised circulating CgA, the gastrin/CCK2 receptor antagonist (CCK2RA), netazepide, reduced the tumour number and size, and normalised CgA.Aim(s): To treat those patients with netazepide for longer, and to identify new biomarkers.Materials and meth...